GSK Completes Breo Ellipta Asthma Study For Potential NDA Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK reports positive results of a Phase III trial comparing the once-daily corticosteroid/long acting beta2-agonist combination Breo to the corticosteroid alone.